SEC v. JianQing Li — U.S. Securities and Exchange Commission Litigation Release No. 26561, dated June 5, 2026.
The SEC charged JianQing Li, a former investment analyst, with insider trading. Li allegedly used confidential information about healthcare companies, obtained through his employer, to trade securities before the information became public, realizing over $320,000 in illicit profits. The SEC seeks injunctions, disgorgement, and penalties.
In Plain English
Imagine you work at a company that helps other companies get ready to share important news, like a new medicine being approved. You learn this secret news before anyone else. Instead of waiting for the news to be public, you secretly buy or sell stocks of those companies to make money. That's what JianQing Li is accused of doing, using secret information from his job to trade stocks and make over $320,000.
Disclaimer: all facts are drawn from the SEC's own filings; the claims described are allegations unless and until a court rules or the parties settle, and some cases end in dismissal.
How the Alleged Scheme Worked
- Gain Access to Confidential Information JianQing Li worked as an investment analyst at a New York-based investment adviser focused on the healthcare sector. His job gave him access to secret information about the firm's clients, including upcoming securities offerings and clinical drug trial results.
- Receive Material Non-Public Information Li's employer would be 'wall-crossed,' meaning they received confidential information about healthcare company clients that they agreed to keep secret. Li was included on communications where this sensitive data was shared.
- Misappropriate Confidential Data Instead of safeguarding the confidential information, Li allegedly misappropriated it for his personal gain. This information included details like the terms of private placements or the outcomes of clinical drug trials.
- Execute Trades Before Public Disclosure Before the material non-public information became public, Li traded in the securities of these healthcare companies. He would buy stock when the news was expected to be favorable and sell short when it was expected to be unfavorable.
- Profit from Price Movements When the companies eventually made their announcements, the stock prices moved sharply. Li would then close his positions, pocketing the profits he made from trading on the non-public information.
- Repeat Across Multiple Companies This pattern of trading occurred at least twelve times between February 2024 and October 2025, involving at least twelve different healthcare companies.
- Conceal Trading Activities Li allegedly hid his trading activities from his employer, whose written policies prohibited trading in healthcare securities. He never sought preclearance for any trades or disclosed his personal brokerage accounts.
- Certify Compliance Falsely Li signed annual certifications stating he had read and would follow his employer's policies, despite allegedly engaging in prohibited trading activities.
The Enforcement Action
On June 5, 2026, the SEC charged JianQing Li with insider trading in the securities of at least twelve healthcare companies from February 2024 through October 2025. The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, alleges Li misappropriated confidential information obtained through his employment at a registered investment adviser. Li allegedly traded on this information before it became public, realizing over $320,000 in illicit profits. The SEC seeks a permanent injunction, disgorgement with prejudgment interest, civil penalties, and a conduct-based injunction prohibiting Li from acting as or associating with an investment adviser. A parallel criminal action was brought by the U.S. Attorney’s Office for the Southern District of New York on the same date.
Named in this action: JianQing Li.